这结果。。。_老虎社区_美港股上老虎

Walt3089
2021-11-26

这结果。。。

Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults

MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death

Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":877674376,"tweetId":"877674376","gmtCreate":1637931039692,"gmtModify":1637931039692,"author":{"id":3554197581285961,"authorId":3554197581285961,"authorIdStr":"3554197581285961","name":"Walt3089","avatar":"https://static.tigerbbs.com/bd3c278053307849b48984268911f507","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>这结果。。。</p></body></html>","htmlText":"<html><head></head><body><p>这结果。。。</p></body></html>","text":"这结果。。。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/877674376","repostId":2186331055,"repostType":2,"repost":{"id":"2186331055","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1637928720,"share":"https://www.laohu8.com/m/news/2186331055?lang=&edition=full","pubTime":"2021-11-26 20:12","market":"us","language":"en","title":"Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2186331055","media":"Dow Jones","summary":"MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death","content":"<p>MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults</p>\n<p>Merck <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death in at-risk adults with mild-to-moderate COVID to 6.8% from 9.7% in the placebo group in the latest update of data from its study dubbed MOVe-OUT. That is equal to an absolute risk reduction of 3.0% and a relative risk reduction of 30%. \"Nine deaths were reported in the placebo group, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> in the molnupiravir group,\" the companies said in a joint statement. \"The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.\" The companies have shared this latest data with the Food and Drug Administration, which is currently reviewing the data for a possible emergency use authorization for the treatment. Antiviral are expected to become a game changer in the pandemic as they can be easily taken at home, unlike existing treatments which must be administered either by infusion or subcutaneously in a clinical setting. Merck shares were down 2.8% premarket.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-11-26 20:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults</p>\n<p>Merck <a href=\"https://laohu8.com/S/MRK\">$(MRK)$</a> and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death in at-risk adults with mild-to-moderate COVID to 6.8% from 9.7% in the placebo group in the latest update of data from its study dubbed MOVe-OUT. That is equal to an absolute risk reduction of 3.0% and a relative risk reduction of 30%. \"Nine deaths were reported in the placebo group, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> in the molnupiravir group,\" the companies said in a joint statement. \"The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.\" The companies have shared this latest data with the Food and Drug Administration, which is currently reviewing the data for a possible emergency use authorization for the treatment. Antiviral are expected to become a game changer in the pandemic as they can be easily taken at home, unlike existing treatments which must be administered either by infusion or subcutaneously in a clinical setting. Merck shares were down 2.8% premarket.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","BK4516":"特朗普概念","MRK":"默沙东","BK4559":"巴菲特持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186331055","content_text":"MW Merck and Ridgeback Biotherapeutics says COVID antiviral reduced risk of hospitalization or death in at-risk adults\nMerck $(MRK)$ and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death in at-risk adults with mild-to-moderate COVID to 6.8% from 9.7% in the placebo group in the latest update of data from its study dubbed MOVe-OUT. That is equal to an absolute risk reduction of 3.0% and a relative risk reduction of 30%. \"Nine deaths were reported in the placebo group, and one in the molnupiravir group,\" the companies said in a joint statement. \"The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.\" The companies have shared this latest data with the Food and Drug Administration, which is currently reviewing the data for a possible emergency use authorization for the treatment. Antiviral are expected to become a game changer in the pandemic as they can be easily taken at home, unlike existing treatments which must be administered either by infusion or subcutaneously in a clinical setting. Merck shares were down 2.8% premarket.","news_type":1},"isVote":1,"tweetType":1,"viewCount":973,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":9,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}